Genomill and Finland’s Cancer Research Flagship iCAN Partner To Improve Cancer Detection Using an Extensive Biobank Cohort
Helsinki, Finland – June 13, 2023 – Genomill and iCAN, the Finnish national cancer research flagship project, signed a partnership aiming to improve the detection of trace tumour DNA from thousands of biobank samples.
Seminal presentation of first analytical validation data scheduled for june 30
NEW YORK – After closing an investment round last month for an undisclosed sum, Finnish firm Genomill Health is aiming to broaden adoption of its Geno1 technology, a barcoding-based method that it believes can enhance sequencing accuracy and lower costs and turnaround time for applications with high sensitivity and efficiency demands like liquid biopsy. The […]
Genomill Health closes a financing round led by a deep tech VC Voima Ventures to expand its novel and disruptive technology, focusing on efficient use of NGS (next generation sequencing) in liquid biopsies for cancer diagnostics.